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ABSTRACT Antibiotic resistance is a global crisis that threatens our ability to treat
bacterial infections, such as tuberculosis, caused by Mycobacterium tuberculosis. Of
the 10 million cases of tuberculosis in 2017, approximately 19% of new cases and
43% of previously treated cases were caused by strains of M. tuberculosis resistant to
at least one frontline antibiotic. There is a clear need for new therapies that target
these genetically resistant strains. Here, we report the discovery of a new series of
antimycobacterial compounds, 4-amino-thieno[2,3-d]pyrimidines, that potently in-
hibit the growth of M. tuberculosis. To elucidate the mechanism by which these
compounds inhibit M. tuberculosis, we selected for mutants resistant to a representa-
tive 4-amino-thieno[2,3-d]pyrimidine and sequenced these strains to identify the mu-
tations that confer resistance. We isolated a total of 12 resistant mutants, each of
which harbored a nonsynonymous mutation in the gene qcrB, which encodes a subunit
of the electron transport chain (ETC) enzyme cytochrome bc1 oxidoreductase, leading us
to hypothesize that 4-amino-thieno[2,3-d]pyrimidines target this enzyme complex. We
found that addition of 4-amino-thieno[2,3-d]pyrimidines to M. tuberculosis cultures
resulted in a decrease in ATP levels, supporting our model that these compounds
inhibit the M. tuberculosis ETC. Furthermore, 4-amino-thieno[2,3-d]pyrimidines had
enhanced activity against a mutant of M. tuberculosis deficient in cytochrome
bd oxidase, which is a hallmark of cytochrome bc1 inhibitors. Therefore, 4-amino-
thieno[2,3-d]pyrimidines represent a novel series of QcrB inhibitors that build on the
growing number of chemical scaffolds that are able to inhibit the mycobacterial cy-
tochrome bc1 complex.
IMPORTANCE The global tuberculosis (TB) epidemic has been exacerbated by the
rise in drug-resistant TB cases worldwide. To tackle this crisis, it is necessary to iden-
tify new vulnerable drug targets in Mycobacterium tuberculosis, the causative agent
of TB, and develop compounds that can inhibit the bacterium through novel mecha-
nisms of action. The QcrB subunit of the electron transport chain enzyme cyto-
chrome bc1 has recently been validated to be a potential drug target. In the current
work, we report the discovery of a new class of QcrB inhibitors, 4-amino-thieno[2,3-
d]pyrimidines, that potently inhibit M. tuberculosis growth in vitro. These compounds
are chemically distinct from previously reported QcrB inhibitors, and therefore,
4-amino-thieno[2,3-d]pyrimidines represent a new scaffold that can be exploited to
inhibit this drug target.
KEYWORDS CydAB, Mycobacterium tuberculosis, QcrB, antibiotic, cytochrome, drug
discovery, respiration
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Infection with Mycobacterium tuberculosis resulted in over 9 million new cases oftuberculosis (TB) and 1.5 million deaths in 2017, making it the most deadly infectious
agent in the world (1). This epidemic is exacerbated by the rise of multidrug-resistant
(MDR) TB cases that are resistant to at least the two frontline antibiotics used to treat
TB, isoniazid and rifampin. MDR-TB constituted 3.6% of new TB cases in 2017 and 17%
of previously treated TB cases, with rates of MDR-TB being as high as 50% among
previously treated TB cases in some countries (1). Furthermore, 8.5% of MDR-TB cases
in 2017 were estimated to be extensively drug resistant (XDR), which are also resistant
to a fluoroquinolone and a second-line injectable drug (1). This rise in drug resistance
and the scarcity of drugs in the pipeline have made it clear that we are not equipped
to successfully battle the ongoing TB epidemic.
In 2012, the diarylquinoline compound bedaquiline (Sirturo), which inhibits the
mycobacterial ATP synthase (2), was approved to treat MDR-TB patients (3). The success
of this new anti-TB antibiotic fueled interest in mycobacterial energy metabolism
pathways as vulnerable targets for new antibiotic development. More recently, the
imidazopyridine amide (IPA) Q203 (telacebec) was identified to be a potent antimyco-
bacterial compound that targets QcrB, a subunit of the mycobacterial cytochrome
bc1:aa3 oxidoreductase in the electron transport chain (ETC) (4). Q203 is currently in
phase II clinical trials for the treatment of TB (5). Since the discovery of Q203 and
additional imidazopyridine amides (4, 6–10), a number of compounds have been
identified that are also reported to target QcrB, including pyrazolo[1,5-a]pyridine-3-
carboxamides (11–13), imidazo[2,1-b]thiazole-5-carboxamides (14), pyrrolo[3,4-c]pyridine-
1,3(2H)-diones (15), lansoprazole sulfide (16), 2-(quinolin-4-yloxy)acetamides (17, 18),
arylvinylpiperazine amides (19), phenoxyalkylbenzimidazoles (20–22), and morpholino
thiophenes (23).
Here, we present the discovery of 4-amino-thieno[2,3-d]pyrimidines as a new series
of QcrB inhibitors that potently inhibit M. tuberculosis growth and that are chemically
distinct from previously identified QcrB inhibitors. This work adds to the growing
number of QcrB inhibitors that have recently been identified and contributes to our
understanding of ways to exploit this target in the development of new chemothera-
peutic strategies for TB treatment.
RESULTS
Identification of 4-amino-thieno[2,3-d]pyrimidines with growth-inhibitory ac-
tivity in Mycobacterium smegmatis and M. tuberculosis. In an effort to identify novel
inhibitors of mycobacteria, we screened a selection of 78 small-molecule nucleotide
mimetics purchased from ChemBridge Corporation for compounds that inhibit the
growth of M. smegmatis in a high-throughput liquid culture assay. From these screens,
we identified a 4-amino-thieno[2,3-d]pyrimidine (CB37) that inhibited the growth of M.
smegmatis (Fig. 1A and B). We hypothesized that the charged carboxylate group on
CB37 may greatly reduce penetration through the cell envelope of the mycobacteria
and selected a set of 9 structurally related compounds that did not contain the
carboxylate group but that contained the 2-ethyl-6-methylthieno[2,3-d]pyrimidine core
(nearest neighbors) to purchase and assay for inhibition of M. smegmatis (Fig. 1; see also
Fig. S1 and entries 2 to 10 in Table S1 in the supplemental material). Eight of the
compounds showed either similar levels of growth inhibition against M. smegmatis as
CB37 or no growth inhibition at all (Fig. S1). However, one of these compounds, CB81,
showed improved growth inhibition in M. smegmatis (Fig. 1C and D). We resynthesized
CB81 and henceforth designate it CWHM-728.
To determine if CWHM-728 also had activity against M. tuberculosis, we performed
zone-of-inhibition assays with the wild-type (WT) M. tuberculosis Erdman strain by
spreading approximately 2.5  108 CFU of bacteria on an agar plate and spotting 5 l
of a 100 mM stock of CWHM-728 dissolved in dimethyl sulfoxide (DMSO) onto a disk in
the center of the plate. After incubation at 37°C for 10 days, the bacteria formed a lawn
and a zone absent of bacterial growth indicated growth inhibition by the compound.
DMSO had no effect on M. tuberculosis growth in this assay and did not generate a zone
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of clearing on its own, whereas incubation of M. tuberculosis with CWHM-728 resulted
in growth inhibition (Fig. 2A). To test if CWHM-728 has a bacteriostatic or a bactericidal
effect on M. tuberculosis, we cultured M. tuberculosis in liquid medium in the presence
of DMSO or 5 M or 25 M CWHM-728 and enumerated the viable CFU after 14 days
of incubation (Fig. 2B). While exposure to 5 M CWHM-728 for 14 days caused a slight
but not statistically significant decrease in the number of CFU compared to that for the
DMSO-treated control, exposure to 25 M CWHM-728 caused a significant reduction in
the number of CFU per milliliter compared to that for the DMSO-treated control.
However, exposure to CWHM-728 did not decrease the number of viable CFU below the
number of initial CFU on day 0, indicating that over 14 days, this concentration of
CWHM-728 had a bacteriostatic effect on M. tuberculosis.
To identify the half-maximal inhibitory concentration (IC50) of CWHM-728 against M.
tuberculosis, we used a microplate alamarBlue assay (MABA), which is a high-
throughput assay commonly used to evaluate the efficacy of antimycobacterial com-
pounds (24). The MABA utilizes the redox-sensitive dye resazurin, which is blue in its
oxidized form but becomes reduced to the pink fluorescent compound resorufin as a
result of bacterial metabolism and respiration. Fluorescence can therefore be quantified
as a readout for M. tuberculosis metabolism and respiration, which serves as a proxy for
M. tuberculosis growth and/or survival. We incubated M. tuberculosis in the presence of
increasing concentrations of CWHM-728 and found that CWHM-728 inhibited M. tuber-
culosis in the MABA with an IC50 of 2.7  0.84 M (Fig. 2C).
To explore chemical modifications that would improve upon the growth-inhibitory
activity of CWHM-728 and develop structure-activity relationships (SAR), we used the
MABA to test if the analogs that we had previously obtained in which the n-butyl side
chain was replaced with other aliphatic groups had inhibitory activity against M.
tuberculosis (see entries 1 to 10 in Table S1). Analogs that had side chains with ionizable
groups (entries 1 and 3) and polar groups, such as hydroxyl (entry 4), had poor activity,
FIG 1 CB37 and CB81 are 4-amino-thieno[2,3-d]pyrimidines that inhibit the growth of M. smegmatis. (A)
Structure of CB37. (B) M. smegmatis (Msm) strain csm208 (Table 2) was incubated in LB medium in the
presence of DMSO, 100 M CB37, or 73 M rifampin (Rif), and the optical density at 600 nm (OD600) was
measured periodically over the course of 12 h in a plate reader (n  2 replicates). (C) Structure of CB81,
which was resynthesized and renamed CWHM-728. (D) M. smegmatis strain csm208 was incubated in LB
medium in the presence of DMSO, 100 M CB81, or 73 M rifampin, and the OD600 was measured over
the course of 12 h in a plate reader (n  3 replicates).
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with IC50 values being greater than 25 M. Capping the hydroxyl group as methoxy
(entries 5 and 6) restored some potency, and isopropoxy (entry 7) yielded a compound
8-fold more potent than the compound with a butyl side chain (entry 2). Cyclopropyl
was tolerated (entry 8), with a submicromolar IC50, while slightly bulkier cyclopentyl
and piperidine side chains resulted in very poor potency (entries 9 and 10).
To further extend the SAR, we synthesized analogs of CWHM-728 containing
lipophilic side chains, and the resulting analogs were evaluated in the MABA (Table S2).
Replacing the n-butyl side chain with t-butyl caused a nearly 10-fold decrease in
potency (entry 2), but trifluoro-n-butyl and isopentyl variants (entries 3 and 4) were
found to be greater than 10-fold more potent than the original n-butyl (entry 1).
Capping the NH with a methyl group (entry 5) demonstrated little effect on potency.
Finally, a series of phenyl and alkylphenyl side chains was prepared and showed
remarkable SAR, with potency being strongly dependent on chain length (entries 6
to 9).
The most potent compound from our SAR evaluation was CWHM-1023, which
shared the 4-amino-thieno[2,3-d]pyrimidine core scaffold with CWHM-728 but which
contained a 3-phenylpropyl side chain (Fig. 3A). We found that CWHM-1023 inhibited
M. tuberculosis growth in the zone-of-inhibition assay (Fig. 3B) and inhibited M. tuber-
culosis in the MABA with an IC50 of 83  5.4 nM (Fig. 3C). This is a 38-fold improvement
in potency compared to that of CWHM-728, which had an IC50 of 3.2  0.13 M in this
FIG 2 CWHM-728 is a 4-amino-thieno[2,3-d]pyrimidine compound that exhibits anti-M. tuberculosis
activity. (A) A zone-of-inhibition assay was performed by spreading 2.5  108 CFU of M. tuberculosis on
a plate containing 7H11 agar medium, placing a sterile disk in the center, and pipetting 5 l of 100%
DMSO or 100 mM CWHM-728 on the disk. The plate was incubated at 37°C for 10 days. Representative
images from at least 3 independent experiments are shown. (B) M. tuberculosis (Mtb) was incubated in
7H9 liquid medium in the presence of DMSO or CWHM-728 at the indicated concentrations. At the
indicated time points, samples were collected and plated onto 7H11 agar medium containing no
antibiotics to enumerate the CFU per milliliter (n  3 replicates). Statistical comparisons for the number
of CFU per milliliter on the final day of the treatment are depicted. P values were determined by two-way
analysis of variance with Tukey’s posttest. *, P  0.05; ns, not significant. (C) M. tuberculosis was incubated
with increasing concentrations of CWHM-728, and bacterial respiration and metabolism were measured
using the MABA (n  3 replicates). The best-fit curve and IC50 values  standard deviation were
calculated using GraphPad Prism software.
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experiment (Fig. 3C). Thus, CWHM-728 and CWHM-1023 are 4-amino-thieno[2,3-
d]pyrimidines that inhibit M. tuberculosis at low micromolar and submicromolar con-
centrations, respectively. Following this same trend in potency, we found that the IC50s
of CWHM-728 and CWHM-1023 for M. smegmatis in the MABA were 52  16 M and
1.7  0.49 M, respectively (Fig. 3D).
Mutations in qcrB confer resistance to 4-amino-thieno[2,3-d]pyrimidines. To
identify the target of the 4-amino-thieno[2,3-d]pyrimidines, we selected for M. tuber-
culosis mutants that were resistant to CWHM-728 by plating approximately 2.5  108
CFU of WT M. tuberculosis Erdman on 7H11 agar medium containing 10 M CWHM-728
and incubating the culture at 37°C for 12 weeks. We found that spontaneous CWHM-
728-resistant mutant colonies emerged at an approximate frequency of 1 in 2.3  107.
To identify the genetic basis for CWHM-728 resistance, we performed whole-genome
sequencing on four CWHM-728-resistant strains and found that all four strains harbored
missense mutations in the qcrB gene. Three of the strains, isolated from a single culture,
had mutations resulting in an A178T amino acid change, and one strain, isolated from
a second independent culture, had a mutation generating a V338G substitution (Ta-
ble 1). We then sequenced the qcrB locus in 8 additional CWHM-728-resistant mutants
isolated from a third independent culture and identified a missense mutation in qcrB in
every isolate (Table 1). One strain harbored the A178T mutation, and 3 more had the
V338G mutation that we had isolated previously. In addition, we found that the
remaining isolates harbored a A178V, G175S, or G315S mutation in qcrB.
The qcrB gene is located within an operon containing ctaE, qcrC, and qcrA. The
qcrCAB gene cassette encodes all 3 subunits of the cytochrome bc1 complex (25). This
complex is localized to the plasma membrane and forms a supercomplex with the
aa3-type cytochrome oxidase encoded by ctaBCDE (26, 27). The resulting cytochrome
bc1:aa3 oxidase complex catalyzes the terminal electron transfer reaction in the myco-
FIG 3 CWHM-1023 is a 4-amino-thieno[2,3-d]pyrimidine with enhanced activity against mycobacteria.
(A) Chemical structure of CWHM-1023. (B) Zone-of-inhibition assay with CHWM-1023. M. tuberculosis
(2.5  108 CFU) was spread on a plate containing 7H11 agar medium, a sterile disk was placed in the
center, and 5 l of 100 mM CWHM-1023 was pipetted onto the disk. The plate was incubated at 37°C for
10 days. A representative image from at least 2 independent experiments is shown. (C and D) M.
tuberculosis (Mtb) (C) or M. smegmatis (Msm) (D) was incubated in the presence of increasing concen-
trations of either CWHM-728 or CWHM-1023, before bacterial respiration and metabolism were measured
using the MABA (n  3 replicates). Best-fit curves and IC50 values were calculated using GraphPad Prism
software. P values were determined by Student’s t test. **, P  0.01; ****, P  0.0001.
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bacterial ETC, transferring electrons from menaquinol, the lipid electron carrier in the
membrane, to the terminal electron acceptor oxygen. We sought to confirm that
mutations in qcrB were sufficient to confer resistance to 4-amino-thieno[2,3-
d]pyrimidines to rule out the possibility that the CWHM-728-resistant mutants harbored
mutations elsewhere in the genome that contributed to resistance. For these studies,
we engineered M. tuberculosis strains that expressed either WT qcrCAB (qcrCABWT) or
qcrCAB with the A178T substitution (qcrCABA178T) from the chromosomal attB site and
deleted the endogenous qcrCAB locus. We then monitored the activity of CWHM-728
(Fig. 4A) and CWHM-1023 (Fig. 4B) against these strains using the MABA. We found that
the strain expressing qcrCABA178T exhibited reduced sensitivity to both compounds
compared to that of WT M. tuberculosis or the isogenic qcrCABWT control strain,
confirming that this single amino acid change in qcrB confers resistance to 4-amino-
thieno[2,3-d]pyrimidines. These data are consistent with a model in which the 4-amino-
thieno[2,3-d]pyrimidines target cytochrome bc1.
TABLE 1 CWHM-728-resistant isolates harbor mutations in qcrBa
Culture no. and resistant strain Mutation in qcrB














aThe CWHM-728-resistant strains isolated in this study are listed with the mutation identified in qcrB.
bThe mutations were identified by whole-genome sequencing. All other mutations were identified by Sanger
sequencing of the qcrB locus.
FIG 4 A mutation in qcrB confers resistance to 4-amino-thieno[2,3-d]pyrimidines. The M. tuberculosis
(Mtb) WT or the M. tuberculosis ΔqcrCAB mutant complemented with either qcrCABWT or qcrCABA178T was
incubated in the presence of increasing concentrations of CWHM-728 (A) or CWHM-1023 (B), and then
bacterial respiration and metabolism were measured using the MABA (n  3). Best-fit curves and IC50
values  standard deviation (S.D.) were calculated using GraphPad Prism software. ns, not significant by
Student’s t test.
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Based on our finding that mutations in the qcrB gene confer resistance to 4-amino-
thieno[2,3-d]pyrimidines, we propose that this new class of antimycobacterial com-
pounds targets QcrB. To better understand how mutations in qcrB confer resistance to
4-amino-thieno[2,3-d]pyrimidines, we used computational modeling to predict the
structure of the M. tuberculosis QcrB protein based on a previously published structure
for QcrB from Rhodobacter sphaeroides, which shares 16% amino acid identity with the
M. tuberculosis QcrB (28) (Fig. 5A). We docked CWHM-728 onto the predicted structure
of QcrB and found that it localized near the putative menaquinol binding site of
QcrB. Based on our computational model, we speculate that the A178T, A178V, or
G175S mutation in QcrB would disrupt the contacts required for 4-amino-thieno[2,3-
d]pyrimidines to bind QcrB (Fig. 5B). The V338 and G315 residues are not located where
they would directly interact with CWHM-728 but are positioned on neighboring helices
within a very tightly packed region, such that changes in amino acid identity could
possibly affect the position of those helices and disrupt the 4-amino-thieno[2,3-
d]pyrimidine binding site.
The predicted binding site for the 4-amino-thieno[2,3-d]pyrimidines is similar to
what has previously been reported from similar modeling studies for the QcrB inhibitor
Q203 (29). We investigated whether the 4-amino-thieno[2,3-d]pyrimidine-resistant
strain expressing qcrCABA178T was more resistant to Q203 than the isogenic qcrCABWT
control strain and found that the qcrBA178T mutation did not affect Q203 sensitivity
in the MABA (Fig. S2). These data suggest that while the qcrBA178T allele is sufficient
to confer resistance to 4-amino-thieno[2,3-d]pyrimidines, it does not confer cross-
resistance to Q203, possibly because the A187T mutation is not sufficient to disrupt the
binding of Q203 to QcrB.
4-Amino-thieno[2,3-d]pyrimidines deplete ATP levels in M. smegmatis and M.
tuberculosis. Based on our model that 4-amino-thieno[2,3-d]pyrimidines target the
QcrB subunit of cytochrome bc1, we hypothesized that CWHM-728 and CWHM-1023
inhibit the mycobacterial ETC. To test this hypothesis, we incubated M. tuberculosis in
the presence of 1 M CWHM-728, 1 M CWHM-1023, or 400 nM Q203 for 24 h and
measured the ATP levels in the bacteria using the BacTiter-Glo assay (Promega). We
found that treatment with CWHM-728, CWHM-1023, and Q203 decreased the ATP levels
in M. tuberculosis by 75%, 60%, and 58%, respectively (Fig. 6A). Similar results were
observed in M. smegmatis, where 10 M CWHM-1023 caused a 41% decrease in ATP
levels in M. smegmatis (Fig. 6B). These data support the possibility that 4-amino-
thieno[2,3-d]pyrimidines target a complex involved in energy generation, consistent
with our hypothesis that these compounds inhibit QcrB in the mycobacterial ETC.
M. smegmatis and M. tuberculosis lacking cytochrome bd are hypersensitive to
4-amino-thieno[2,3-d]pyrimidines. Mycobacteria have a branched ETC that can ter-
FIG 5 Molecular modeling of CWHM-728 in the predicted structure of M. tuberculosis QcrB. (A) QcrB
homology model embedded in the lipid bilayer, with the lipid head group phosphorus being shown as
magenta spheres. (B) QcrB binding site shown with CHWM-728 docked (green). The residues mutated in
resistant mutants are highlighted in magenta.
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minate either in the cytochrome bc1:aa3 terminal oxidase or in the cytochrome bd
terminal oxidase, encoded by cydAB (25, 30). Cytochrome bc1:aa3 oxidase and cyto-
chrome bd oxidase have somewhat overlapping roles in the ETC to transfer electrons
from menaquinol to oxygen, where the cytochrome bd oxidase can partially compen-
sate for the loss of cytochrome bc1:aa3 oxidase activity, as evidenced by the observa-
tion that mutants of cytochrome bd exhibit increased sensitivity to cytochrome bc1
inhibitors (8, 31). Therefore, we hypothesized that 4-amino-thieno[2,3-d]pyrimidines
would exhibit enhanced activity against mycobacteria lacking cytochrome bd com-
pared with that of the WT strains. To test this hypothesis, we generated M. tuberculosis
ΔcydA and M. smegmatis ΔcydA mutants, which lack cytochrome bd, and measured the
sensitivity of these mutant strains to 4-amino-thieno[2,3-d]pyrimidines compared to
that of the WT strains. We found that deletion of cydA increased the sensitivity of M.
tuberculosis to CWHM-728 13.8-fold (Fig. 7A), CWHM-1023 22.6-fold (Fig. 7B), and Q203
7.7-fold (Fig. 7C), as measured by a decrease in the MABA IC50 compared to that for WT
M. tuberculosis. Additionally, we found that CWHM-1023 had a 4.6-fold lower IC50
against M. smegmatis ΔcydA than against WT M. smegmatis, which was partially
complemented by expressing cydAB in this strain (Fig. 7D). These data demonstrate that
genetic deletion of cytochrome bd sensitizes mycobacteria to inhibition by 4-amino-
thieno[2,3-d]pyrimidines, which is consistent with our hypothesis that these com-
pounds target the QcrB subunit of cytochrome bc1.
DISCUSSION
There is a dire need for new anti-TB drugs that shorten treatment regimens and that
are effective against MDR and XDR strains of M. tuberculosis. To begin to address this
need, two anti-TB agents have recently received accelerated regulatory approval from
the U.S. Food and Drug Administration (FDA) (3). These two drugs, bedaquiline (Sirturo)
and delamanid, are the first antibiotics to be approved for the treatment of TB in the
last 50 years (32). The discovery and development of bedaquiline in particular have
raised general interest in targeting M. tuberculosis ETC and respiration as a therapeutic
strategy.
Simultaneously, numerous phenotypic screens have identified QcrB inhibitors that
inhibit the growth of M. tuberculosis in axenic culture and/or in macrophages (4, 8, 15,
16, 19, 21, 23, 33), raising further interest in the ETC as a drug target. The most clinically
FIG 6 4-Amino-thieno[2,3-d]pyrimidines deplete mycobacterial ATP levels. (A) M. tuberculosis (Mtb) was
incubated in the presence of 1 M CWHM-728, 1 M CWHM-1023, or 400 nM Q203 for 24 h, the samples
were heat inactivated, and ATP was quantified using the BacTiter-Glo assay (n  3). (B) M. smegmatis
(Msm) was incubated in the presence of 10 M CWHM-1023 for 12 h, and ATP was quantified using the
BacTiter-Glo assay (n  3). In both panels, ATP levels were normalized to the number of log10 CFU to
account for differences in bacterial numbers due to differences in growth. P values were determined by
one-way analysis of variance with Tukey’s posttest (A) or Student’s t test (B). ***, P  0.001; ****,
P  0.0001; ns, not significant.
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advanced of these QcrB inhibitors is the imidazopyridine amide (IPA) Q203 (telacebec),
which is currently in clinical trials for the treatment of TB (5). In this study, we report the
discovery of a novel class of QcrB inhibitors, 4-amino-thieno[2,3-d]pyrimidines, that are
chemically distinct from the previously identified QcrB inhibitors. Therefore, the new
chemical scaffold described here adds to the growing chemical space that can be
exploited to target the mycobacterial cytochrome bc1 complex. The most potent
4-amino-thieno[2,3-d]pyrimidine inhibitor of QcrB that we identified, CWHM-1023,
had an IC50 of approximately 83 nM for M. tuberculosis in the MABA assay (see Table S2
in the supplemental material). This is in comparison with the IC50s for the known
respiration inhibitors Q203, bedaquiline, and thioridazine, which are 1.5 nM, 78 nM,
and 11.2 M, respectively, against M. tuberculosis in the MABA (Table S2).
Mycobacteria have a branched ETC, whereby electrons can be shuttled either to
cytochrome bc1 or to cytochrome bd to be transferred to the terminal electron
acceptor, O2 (30). Cytochrome bc1 is proposed to be bioenergetically more efficient
than cytochrome bd under standard aerobic conditions (25). However, cytochrome bd
is induced under conditions of low oxygen and contributes to mycobacterial fitness
under microaerobic conditions, suggesting that cytochrome bd can support mycobac-
FIG 7 Mycobacteria lacking cytochrome bd have increased sensitivity to 4-amino-thieno[2,3-d]pyrimidines. (A to
C) Either WT M. tuberculosis (Mtb) or M. tuberculosis ΔcydA was incubated in the presence of increasing concen-
trations of CWHM-728 (A), CWHM-1023 (B), or Q203 (C), and respiration and metabolism were measured using the
MABA (n  3 replicates). (D) WT M. smegmatis (Msm) or M. smegmatis ΔcydA complemented with the empty vector
(EV) or with a plasmid harboring cydAB was incubated in the presence of increasing concentrations of CWHM-1023,
and respiration and metabolism were measured using the MABA (n  3 replicates). (A to D) Best-fit curves and IC50
values  standard deviation (S.D.) were generated using GraphPad Prism software. P values were determined by
Student’s t test (A to C) or one-way analysis of variance with Tukey’s posttest (D). *, P  0.05; ****, P  0.0001; ns,
not significant.
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terial survival under certain conditions (30). As such, while cytochrome bc1 is important
for the growth of M. tuberculosis under laboratory conditions (25, 34–36), M. tuberculosis
is able to survive during inhibition of cytochrome bc1 (37, 38), which is consistent with
our data (Fig. 2B) and previously reported data indicating that QcrB inhibitors lack early
bactericidal activity and are bacteriostatic for several weeks (19, 20, 31). Furthermore, it
was reported that treatment of an M. tuberculosis mutant lacking cytochrome bd with
QcrB inhibitors results in bacterial death (19, 31). Conversely, it was found that
overexpression of cytochrome bd in M. tuberculosis can enable the bacteria to grow,
despite cytochrome bc1 inhibition (8, 39). Together, these data indicate that cyto-
chrome bd can compensate for cytochrome bc1 inhibition.
Expression of cytochrome bc1 and cytochrome bd has also been shown to change
throughout the course of infection. In mice infected with M. tuberculosis, it was found
that qcrC expression was the highest during acute infection (day 15) and that following
20 days of infection qcrC was transcriptionally downregulated 2- to 2.5-fold. In contrast,
cydA was transcriptionally upregulated after 20 days, with the highest level of expres-
sion being detected at 30 days postinfection, when there was a 7-fold increase over the
day 15 expression levels (40). These findings suggest that M. tuberculosis may rely more
heavily on cytochrome bc1 during acute stages of infection, whereas cytochrome bd is
activated at later stages of infection. These expression patterns may explain why it has
been found that QcrB inhibitors work well to halt M. tuberculosis growth in the mouse
when administered during the acute phase of infection (4, 12, 16, 19) but have a
variable impact on the bacterial burden when treatment starts after the mice have been
infected for more than 2 weeks, with most studies reporting modest decreases in the
bacterial burden, if any decrease at all (4, 12, 19, 31). Some of the variability of QcrB
inhibitor efficacy during the later stages of infection likely also depends on the timing
of the treatment and the dosing of the compound.
Given the respiratory flexibilty in M. tuberculosis, interest has increased in using
combinations of antibiotics that target different components of the ETC, a strategy that
has been shown to lead to synergy in bactericidal effects (38, 41, 42). In particular, our
studies with 4-amino-thieno[2,3-d]pyrimidines in the ΔcydA mutants imply that inhibi-
tion of QcrB would have an enhanced impact on M. tuberculosis in combination with
inhibitors of cytochrome bd, as previously observed for Q203 (42). Together, these
findings indicate that 4-amino-thieno[2,3-d]pyrimidines target QcrB and highlight the
idea that the concurrent inhibition of both cytochrome bc1 and cytochrome bd is more
effective than inhibition of cytochrome bc1 alone. In addition to potentiating other
respiration inhibitors, a QcrB inhibitor has recently been shown to enhance pyrazin-
amide as well as rifampin monotherapy in mice, indicating that QcrB inhibitors may
prove to be a useful addition to the current standard of care (12).
MATERIALS AND METHODS
Bacterial strains and growth conditions. M. tuberculosis Erdman was cultured in Middlebrook 7H9
liquid medium supplemented with 60 l/liter oleic acid, 5 g/liter bovine serum albumin, 2 g/liter
dextrose, and 0.003 g/liter catalase (OADC) plus 0.5% glycerol and 0.05% Tween 80. For solid medium,
Middlebrook 7H10 or 7H11 agar medium supplemented with OADC and 0.5% glycerol was used. M.
smegmatis mc2155 was cultured in LB medium supplemented with 0.5% glycerol, 0.5% dextrose, and
0.05% Tween 80. Genetic deletion mutant strains of M. tuberculosis and M. smegmatis (Table 2) were
generated using specialized transduction with the conditionally replicating phage phAE87 as previously
described (43, 44). When appropriate, mycobacterial strains were selected on 20 g/ml kanamycin
and/or 50 g/ml hygromycin.
Initial screen. Logarithmically growing M. smegmatis strain csm208 was inoculated into 96-well
dishes containing 100 M compounds in 200 l LB at a starting optical density at 600 nm (OD600) of 0.2
and incubated with shaking at 37°C in a Tecan M200 Pro plate reader, with OD600 measurements being
taken in each well every 15 s.
Microplate alamarBlue assays (MABAs). Logarithmically growing M. tuberculosis was inoculated
into 7H9 medium in 96-well plates with wells containing increasing concentrations of compound. M.
tuberculosis was inoculated at an OD600 of 0.0008, corresponding to approximately 4  105 CFU/ml in
200 l per well. The plates were incubated at 37°C in 5% CO2 for 1 week, at which point 32.5 l of a
mixture containing an 8:5 ratio of 0.6 mM resazurin (Sigma) dissolved in 1 phosphate-buffered saline
to 20% Tween 80 was added, and the production of fluorescent resorufin was measured after incubation
at 37°C in 5% CO2 overnight. For M. tuberculosis, samples were removed from the plate and mixed with
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formalin to kill the M. tuberculosis bacteria before measuring the fluorescence. For M. smegmatis, the
assay plate was measured directly. Fluorescence was measured on a Tecan M200 Pro plate reader with
an excitation  of 530 nm and an emission  of 590 nm. For each assay, medium alone served as a
negative control, and untreated M. tuberculosis or M. smegmatis was included as a positive control. The
percent inhibition was calculated as the {[(fluorescence of the positive control  fluorescence of the
negative control)  (fluorescence of the sample  fluorescence of the negative control)]/(fluorescence
of the positive control  fluorescence of the negative control)}  100.
Selection and sequencing of resistant mutants. Resistant mutants were selected on 7H11 agar
medium containing 10 M CWHM-728. Approximately 2.5  108 CFU of WT M. tuberculosis Erdman was
spread per plate, and the plate was incubated at 37°C for 12 weeks. Genomic DNA was isolated using
cetyltrimethylammonium bromide-lysozyme lysis, followed by chloroform-isoamyl alcohol extraction
and isopropanol precipitation, as previously described (45). Whole-genome sequencing was performed
by use of an Illumina HiSeq sequencer with 50-bp single-end reads. The identification of single
nucleotide polymorphisms (SNPs) was done using SeqMan NGen software (DNASTAR). The genomes
were assembled and compared to the genomic DNA from the WT parental control strain to identify SNPs
that may be responsible for resistance to CWHM-728. The mutations identified in qcrB by whole-genome
sequencing were subsequently confirmed by Sanger sequencing. For Sanger sequencing of the qcrB
locus, the genomic region was PCR amplified using primers erdqcrBfwxbaI430 (GTCTAGAATGAGTCCGA
AACTGAGTCCGCC) and RK27 (GAAGCTTTCGCCGGGCTAGTGCTCGCCGTC) and then sequenced using the
same two primers (GeneWiz).
Computational modeling. A homology model of M. tuberculosis QcrB was built using the crystal
structure of Rhodobacter sphaeroides QcrB (PDB accession number 2QJP) (28) as the template structure,
using the sequence alignment from Ko and Choi (29). The model, which was built in the Molecular
Operating Environment (MOE 2016.08; Chemical Computing Group, Montreal, Quebec, Canada), was
placed into a membrane environment (46), and energy was minimized. The geometry of the [2Fe-2S]
center and the disulfide bond pattern adjacent to the inhibitor-binding site were assumed to match
those of the template structure. CWHM-728 was docked into the homology model using the GOLD (v5.5)
program (47).
ATP measurements. M. tuberculosis or M. smegmatis was inoculated into 7H9 medium with or
without the test compounds at an OD600 of 0.1 and incubated with shaking at 37°C for 24 h (M.
tuberculosis) or 12 h (M. smegmatis). An aliquot of the culture was heat inactivated at 95°C for 20 min and
diluted 1:100. Diluted samples were mixed with the BacTiter-Glo assay (Promega) reagent at a 1:1 ratio,
and luminescence was quantified on a Tecan M200 Pro plate reader (integration  1 s). Relative
luminescence units (RLU) were normalized to the number of log10 CFU in the sample to account for
differences in bacterial number.
Compounds. CB37, CWHM-728 (CB81), CWHM-935, CWHM-936, CWHM-941, CWHM-950, CWHM-937,
CWHM-946, CWHM-951, and CWHM-942 were purchased from ChemBridge Corporation. Synthesis of the
compounds CWHM-1069, CWHM-1020, CWHM-1022, CWHM-1021, CWHM-1304, CWHM-1303, CWHM-
1306, and CWHM-1023 is described in Text S1 in the supplemental material, and liquid chromatography-
mass spectrometry (LC-MS), 1H nuclear magnetic resonance (NMR), and 13C NMR analyses were done on
TABLE 2 Strains and plasmids used in this study




qcrCABWT Erdman ΔqcrCAB::Hygr attB::pMSG430-qcrCABMtbWT
qcrCABA178T Erdman ΔqcrCAB::Hygr attB::pMSG430-qcrCABMtbA178T
ΔcydA Erdman ΔcydA::Hygr attB::pMSG430 (EV)
M. smegmatis
WT mc2155
csm208 mc2155 ΔrelA attB::pMSG430-relAMtb53–394
ΔqcrCAB mc2155 ΔqcrCAB::Hygr
ΔcydA  EV mc2155 ΔcydA::Hygr attB::pMSG430 (EV)
ΔcydA  cydAB mc2155 ΔcydA::Hygr attB::pMSG430-cydABMsm
Plasmids
pMSG430 Shuttle vector that harbors the L5 recombinase and attP site and a constitutive Pmyc1-tetO promoter, Kanr
pMSG430-qcrCABMtbWT pMSG430 with qcrCABMtbWT (Pmyc1-tetO promoter)
pMSG430-qcrCABMtbA178T pMSG430 with qcrCABMtbA178T (Pmyc1-tetO promoter)
pMSG430-relAMtb53–394 pMSG430 with relAMtb53–394 (Pmyc1-tetO promoter)
pMSG430-cydABMsm pMSG430 with cydABMsm (Pmyc1-tetO promoter)
pMSG360 Cloning vector that harbors regions of homology to the phAE87 phage genome and multiple cloning sites upstream
and downstream of an Hygr marker for engineering specialized transducing phage, Hygr
pMSG360-qcrCABMtb pMSG360 with homology to Erdman nucleotides 2448245–2448982 and 2452708–2453440
pMSG360-cydAMtb pMSG360 with homology to Erdman nucleotides 1809431–1810193 and 1807061–1808049
pMSG360-qcrCABMsm pMSG360 with homology to mc2155 nucleotides 4344291–4344965 and 4348476–4349188
pMSG360-cydAMsm pMSG360 with homology to mc2155 nucleotides 3317608–3318615 and 3315796–3316290
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CWHM-1023 to confirm the purity and identity of the synthesized compound (Fig. S3 and S4). Q203 was
acquired from Enamine (catalog number EN-300-218150), and both bedaquiline (catalog number
465749185) and thioridazine (catalog number 1662504) were purchased from Sigma-Aldrich; all three
compounds were tested in the MABA for comparative purposes.
Data availability. The sequence data are publicly available in the NCBI Sequence Read Archive under
accession no. PRJNA561987.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
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